Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Drug company will fund rare cancer treatment

  • 1 Comment

The manufacturer of a drug which could extend the lives of thousands of people suffering from a rare form of cancer has agreed to pay for further patient treatment as part of a cost-cutting scheme.

The company PharmaMar has announced it will meet the expense of the cancer drug, called trabectedin, if a patient needs it beyond a fifth cycle.

The decision by NICE means the lives of people suffering with advanced soft tissue sarcoma could be extended by at least three months.

Currently about 2,000 people a year are diagnosed with the disease in the UK, and in England and Wales between 500 and 600 people live with the cancer.

Trabectedin will benefit around 110 patients a year who have failed on other treatments, at a cost of more than £3,500 a cycle.

  • 1 Comment

Readers' comments (1)

  • One of the best way pharmamar can help this group of patients is by lowering the cost of this drug from the onset. Most of these patients currently have to fight tooth and nail for funding and this way it would reduce that unnecessary stress.

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs